Nanogen Stakes A Shape-Shifting Market
Newly abundant genomic data is driving formation of all sorts of technology-based businesses. But markets for new tools are already chaotic and competitive, in part because customers know they've got many choices. Nanogen is in the thick of it. Pharmaceutical researchers weren't so interested in the firm's low-density gene chips, so the firm is now focusing on the clinical diagnostics market where managers believe flexible, accurate NanoChips will be better appreciated. The trouble is, the long-foretold market for molecular diagnostics still barely exists. On one hand, market immaturity spells opportunity for Nanogen as an early entrant, but it also means the company has to bushwhack a new path for its technology. It's not easy. For now, Nanogen is marketing its system to researchers in clinical diagnostic labs, university hospitals and government institutions-scientists at the cutting edge, who may become key content developers. The firm is also working to better serve drug makers. The company's customers display little loyalty yet: they're eager to try other new technologies too. Nanogen is betting that the superiority of its system will win hearts and minds as the market for molecular diagnostics takes shape.
You may also be interested in...
The FDA is now sorting through public comments on draft guidance the agency issued recently, to encourage drug developers to voluntarily share pharmacogenomic data with it. Companies have some serious concerns that the agency means to address by the summer with the issuance of formal guidelines and the launching of a public forum for discussion about pharmacogenomics.
Motorola is developing an expertise in microarray manufacturing to use as the jump-off point for a new life sciences initiative it hopes will turn into a high-margin, high-growth diagnostics business. It has spent $500 million in external investments to support the venture, including the $280 million acquisition of a clinical diagnostics start-up. But with its investors concerned with the recent downturn in demand in its core high-tech manufacturing businesses, the company is understandably reticent about touting the possibility of life sciences being its next big thing. On the other hand, should Motorola gain momentum and demonstrate an ability to tap the clinical diagnostics markets, the biochip initiative could ultimately become a broad-based point-of-care play, with the company drawing on its expertise in wireless communications to produce interactive handheld devices that would capture and transmit data to a remote site for analysis.
Japanese major buys out existing cancer cell therapy research partner, exercising an exclusive option dating back to a 2017 collaboration and expanding its immuno-oncology ambitions and pipeline.